University of Illinois at Chicago
LU-DISSERTATION-2019.pdf (8.64 MB)

Novel Treatment for ER+ Treatment Resistant Breast Cancer

Download (8.64 MB)
posted on 2019-08-06, 00:00 authored by Yunlong Lu
Estrogen receptors (ERs) are nuclear hormone receptors and regulate many target genes associated with cell survival, growth and development. ERs act as transcription factors and bind to estrogen and initiate gene expression that regulates biological activities, such as bone remodeling, cardiovascular system functioning, reproductive organ development, metabolism and behavior. In ER+ breast cancer, ER plays a significant role in emergence, progression and metastasis of disease pathogenesis. Multiple therapeutic approaches have been directly or indirectly targeted at the ER signaling pathway to disturb its function. Selective estrogen receptor modulators (SERMs), i.e. tamoxifen, aromatase inhibitors (AIs) i.e. anatrozole, and selective estrogen receptor degraders (SERDs) i.e. fulvestrant are developed to restrict the bioactivity of ER and serve as endocrine therapy for treatment resistant ER+ breast cancer.



Thatcher, Gregory


Thatcher, Gregory


Medicinal Chemistry and Pharmacognosy

Degree Grantor

University of Illinois at Chicago

Degree Level

  • Doctoral

Committee Member

DiMagno, Steven Johnson, Jeremy Hickok, Jason Moore, Terry Bolton, Judy

Submitted date

May 2019

Issue date


Usage metrics


    No categories selected